Arca
Skip to content
Tools
Tools

SLC12A3: Solute carrier family 12 member 3

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules.

  • Drugs that act on it: 13
  • Approved: 13
  • In phases 1 to 3: 0
  • Sponsors: 10
  • Type: Protein

Who Is On It, and How Far Along

Every drug ChEMBL records acting on SLC12A3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved13

  • Hydrochlorothiazide
  • Chlorothiazide
  • Indapamide
  • Chlorthalidone
  • Metolazone
  • Bendroflumethiazide
  • Benzthiazide
  • Cyclothiazide
  • Hydroflumethiazide
  • Methyclothiazide
  • Polythiazide
  • Quinethazone
  • Trichlormethiazide

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        Modalities

        Drugs on this target by ChEMBL molecule type.

        • Small molecule13100%

        The Landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Thiazide-sensitive sodium-chloride cotransporter inhibitor.
        HydrochlorothiazideApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—25—
        ChlorothiazideApprovedDaiichi SankyoSmall moleculeInhibitor—16—
        IndapamideApprovedSanofiSmall moleculeInhibitor—13—
        ChlorthalidoneApprovedSanofiSmall moleculeInhibitor—11—
        MetolazoneApprovedI3 PharmsSmall moleculeInhibitor—6Boxed warning
        BendroflumethiazideApprovedBristol-Myers SquibbSmall moleculeInhibitor—2—
        BenzthiazideApprovedPfizerSmall moleculeInhibitor—1—
        CyclothiazideApprovedEli LillySmall moleculeInhibitor—0—
        HydroflumethiazideApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor—0—
        MethyclothiazideApprovedAbbVieSmall moleculeInhibitor—0—
        PolythiazideApprovedPfizerSmall moleculeInhibitor—0—
        QuinethazoneApprovedPfizerSmall moleculeInhibitor—0—
        TrichlormethiazideApprovedMerck & Co. (MSD)Small moleculeInhibitor—0—

        Open Trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 35 in all, from ClinicalTrials.gov.
        Blood Pressure Control and Safety of Ex-one or Ex-one Plus in Essential HypertensionChlorthalidone—RecruitingHK inno.N Corporation2026-11-12
        Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential HypertensionHydrochlorothiazidePhase 4Not yet recruitingChina National Center for Cardiovascular Diseases2026-11-12
        Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With HypertensionChlorthalidone—RecruitingHanmi Pharmaceutical Company Limited2026-08-25
        Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)IndapamidePhase 2Not yet recruitingEva M.M. Strijbis2026-08-14
        SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive TherapyHydrochlorothiazide, ChlorothiazidePhase 4Not yet recruitingOttawa Hospital Research Institute2026-07-07
        Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary InterventionHydrochlorothiazideNot applicableRecruitingNational Medical Research Center for Therapy and Preventive Medicine2026-07-06
        Polypills Approach for Multiple Cardiovascular Risk FactorsIndapamideNot applicableRecruitingChina Medical University, China2026-07-01
        LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD TrialChlorthalidonePhase 2Not yet recruitingVA Office of Research and Development2026-06-12
        Vertebrobasilar Dolichoectasia Treatment With AmilorideHydrochlorothiazidePhase 2Not yet recruitingHuashan Hospital2026-06-08
        TACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart FailureHydrochlorothiazide, ChlorothiazidePhase 4Not yet recruitingLucrecia Maria Burgos2026-05-18
        Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesChlorothiazideNot applicableEnrolling by invitationEnhanced Emirates Limited2026-05-06
        POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart FailureHydrochlorothiazide, ChlorothiazidePhase 2 / Phase 3Not yet recruitingHospital de Clinicas de Porto Alegre2026-03-13
        Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure ControlHydrochlorothiazide, ChlorothiazideNot applicableRecruitingThe University of Hong Kong2026-03-09
        PrP-targeting siRNA Safety & Mechanism StudyBenzthiazidePhase 1RecruitingBroad Institute of MIT and Harvard2026-03-03
        A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed ConditionsIndapamidePhase 1Not yet recruitingBoryung Pharmaceutical Co., Ltd2026-02-19
        Add-on Diuretics in Acute Decompensated Heart FailureMetolazonePhase 2RecruitingTanta University2026-01-28
        Blood Pressure Control With Thiazide Diuretics in Peritoneal Dialysis PatientsHydrochlorothiazide, ChlorothiazidePhase 4RecruitingChinese University of Hong Kong2025-12-09
        Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)IndapamideNot applicableRecruitingInstituto Dante Pazzanese de Cardiologia2025-12-02
        Antihypertensive Drug Selection Based on Hemodynamic PhenotypesIndapamidePhase 4Not yet recruitingThe Third Xiangya Hospital of Central South University2025-11-21
        Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of PregnancyChlorthalidonePhase 2RecruitingMassachusetts General Hospital2025-11-20
        Perirenal Adipose Tissue Modification Therapy for Resistant HypertensionIndapamidePhase 3Not yet recruitingYan Li2025-11-18
        CaOx Stone PreventionChlorthalidonePhase 4RecruitingIcahn School of Medicine at Mount Sinai2025-11-10
        Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart FailureMetolazoneNot applicableRecruitingUniversity of Health Sciences Lahore2025-09-30
        Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential HypertensionIndapamidePhase 2Enrolling by invitationShin Poong Pharmaceutical Co. Ltd.2025-07-14
        Treatment With Indapamide in Patients With Post-Surgical HypoparathyroidismIndapamidePhase 4RecruitingLars Rejnmark2025-06-24
        The Role of Skin Sodium Accumulation in Chronic Kidney DiseaseChlorothiazideNot applicableRecruitingAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2025-06-13
        Arterial Stiffness and Blood PressureChlorthalidoneNot applicableRecruitingVA Office of Research and Development2024-07-11
        Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential HypertensionChlorthalidone—Active, not recruitingYuhan Corporation2024-02-28
        Acetazolamide or Metolazone in Acute Heart FailureMetolazoneNot applicableNot yet recruitingClinica Alemana de Santiago2024-02-22
        Diuretics vs. Afterload Reduction for Treatment of HeartLogic AlertsMetolazonePhase 4RecruitingHeart Center Research, LLC2024-01-23
        Mechanisms of Diuretic Resistance in Heart Failure, Aim 3BendroflumethiazidePhase 1RecruitingYale University2024-01-17
        Optimal Diuretic Therapies for Acute Heart Failure With Volume OverloadMetolazonePhase 3RecruitingJohannes Grand2023-12-12
        Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone PreventionChlorthalidone, ChlorothiazidePhase 2RecruitingInsel Gruppe AG, University Hospital Bern2023-11-01
        Mechanisms of Diuretic Resistance in Heart Failure, Aim 2BendroflumethiazidePhase 1RecruitingYale University2023-03-03
        Ertugliflozin in Chronic Heart FailureMetolazonePhase 2RecruitingYale University2020-06-18

        Diseases Most Associated With It

        Open Targets association score, 0 to 1; all associations
        Gitelman syndrome
        0.85
        Hypertensive disorder
        0.66
        Congestive heart failure
        0.61
        Cardiovascular disorder
        0.59
        Edema
        0.58
        Preeclampsia
        0.57
        Stroke disorder
        0.55

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1876, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P55017, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.